|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT03198195 |
|
Date of registration:
|
22/06/2017 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome
|
|
Scientific title:
|
Post-transplant Cyclophosphamide for HLA-haploidentical Transplantation in Wiskott-Aldrich Syndrome |
|
Date of first enrolment:
|
March 10, 2015 |
|
Target sample size:
|
5 |
|
Recruitment status: |
Enrolling by invitation |
|
URL:
|
https://clinicaltrials.gov/show/NCT03198195 |
|
Study type:
|
Observational [Patient Registry] |
|
Study design:
|
|
|
Phase:
|
N/A
|
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
-Patients diagnosed with Wiskott-Aldrich Syndrome with indication of Hematopoietic stem
cell transplantation
Exclusion Criteria:
- without indication of Hematopoietic stem cell transplantation
Age minimum:
5 Months
Age maximum:
10 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Wiskott-Aldrich Syndrome
|
|
Intervention(s)
|
|
Procedure: cyclophosphamide
|
|
Primary Outcome(s)
|
|
Rate of aGvHD
[Time Frame: 3month]
|
|
Secondary ID(s)
|
|
CIP-2015-08
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|